Microbiome Connect: Gut Therapeutics on November 17-18, 2021 in Boston, United States

Clinical data continues to implicate the gut microbiome in an array of indications, evidencing the vast potential as a future drug target and source of biomarkers.

We are approaching a pivotal time in the industry's development. The global human microbiome therapeutics market is forecasted to be worth $ 1,544 million by 2027! With 27% of microbiome drugs are entering phase 2 trials. It is time to cement your foundations to ready yourself for the incoming market boom.

Microbiome Connect: Gut Therapeutics will bring you essential solutions to the array of challenges operating in the microbiome field. The event will facilitate your discussions, uniting academics, biotechs and other industry stakeholders to share their exclusive research and innovation. Hear from big pharma to understand what they look for in a partner.

Join us for two full days of innovation, discussion, and networking opportunities to further develop your knowledge and business opportunities in the gut microbiome therapeutics field.

Microbiome Connect: Where innovation meets industry.

WHAT'S NEW FOR 2021

Deep dive into the microbiome’s mechanistic and metabolomic role in Neurological, Oncological, Gastro-Intestinal & Metabolic indications with three distinct scientific streams of the latest pre-clinical and clinical data.

Assess how leading biotech companies and academics are designing a range of therapeutic microbiome-modulating modalities from small-molecule and Phage to rationally designed live bio-therapeutics and FMT.

Meet your next commercial partner and learn exactly what Pharma and VCs are looking for in terms of pre-clinical and clinical data to finance academic spin-outs and later-stage clinical trials.